Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9000868 | Antiviral Research | 2005 | 10 Pages |
Abstract
A novel low molecular weight compound, CJ 4-16-4, isolated from ethnobotanicals using bioassay-guided fractionation, was found to be a potent inhibitor of respiratory syncytial virus (RSV) in vitro and in vivo. In vitro, a very low micromolar efficacious dose was obtained against at least four of subtype A (RSV-Long, RSV A2, and RSV A6 57754) and one of subtype B (Washington) RSV strains without seeing any significant cytotoxicity to Hep-2, MDCK or Vero cell lines. The drug inhibits growth of RSV in Hep-2 cells maintained in tissue culture at a very low concentration (â¼0.07 μM) with cell toxicity >400 μM (TI > 5880). In a cotton rat model of RSV infection, the drug was able to reduce viral titers by â¼1 log at dose 12.5 and 25 mg/kg/day, and by >2 log at 100 mg/kg/day. This antiviral activity was specific as influenza A and B and herpes simplex 1 and 2 viruses were not inhibited. The results obtained indicate that CJ 4-16-4 warrants clinical development.
Related Topics
Life Sciences
Immunology and Microbiology
Virology
Authors
Joshua O. Ojwang, Yan-Hong Wang, Philip R. Wyde, Nikolaus H. Fischer, Wolfgang Schuehly, James R. Appleman, Soreeta Hinds, Craig D. Shimasaki,